SEC Filing Summary: Athira Pharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. on August 15, 2022. The filing serves to report the Company's financial results for the quarter ended June 30, 2022, as detailed in a press release furnished as Exhibit 99.1. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in Bothell, WA.
Key Financial Metrics
The provided filing text acts as a cover document and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text provided.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of the Q2 2022 financial results.
Guidance, Outlook, and Risks
Regulation FD Disclosure: The Company utilizes various channels to communicate material information, including its website, investor relations portal, and social media accounts (Twitter, LinkedIn, Facebook). Investors are encouraged to monitor these channels for updates on product candidates and other matters.
Unusual Items: None explicitly detailed in the text of this 8-K form.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Press Release) for specific Q2 2022 financial figures (revenue, net loss, cash position).
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check the Company's official website and social media channels for any subsequent updates on product candidates or clinical trial data.
- Confirm the status of the Company's emerging growth company election and any related accounting standard transitions.